Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...
Estimate”Throughout 2024 and now into early 2025, we continue to advance our development portfolio centered around our novel product candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback